Examkin

Question

Difficulty: EasyMonitoring and Treatment Evaluation

A 72-year-old man comes to the clinic for a routine follow-up. He has a history of a mechanical aortic valve replacement performed 4 years ago. He is maintained on a stable daily dose of warfarin, and his international normalized ratio (INR) has consistently remained within the target therapeutic range of 2.5 to 3.5 for the past year. Two weeks ago, the patient was diagnosed with highly symptomatic paroxysmal atrial fibrillation and was started on amiodarone by his cardiologist. He reports no bleeding, bruising, dizziness, or palpitations today. His vital signs are within normal limits, and physical examination is unremarkable. Which of the following is the most appropriate next step in the monitoring and management of this patient's pharmacotherapy?

  1. A
    Continue the current medication regimen and check the international normalized ratio at the next routine 3-month visit
  2. Measure the prothrombin time/international normalized ratio and preemptively decrease the warfarin doseAnswer
  3. C
    Discontinue warfarin and initiate a direct oral anticoagulant such as rivaroxaban
  4. D
    Monitor the activated partial thromboplastin time to guide necessary adjustments to the warfarin dose
  5. E
    Order a non-contrast computed tomography scan of the head to screen for subclinical intracranial hemorrhage

Answer

Measure the prothrombin time/international normalized ratio and preemptively decrease the warfarin dose.
Amiodarone is a well-known, potent inhibitor of several cytochrome P450 enzymes, most notably CYP2C9. Warfarin is administered as a racemic mixture, and its more active S-enantiomer is primarily metabolized by CYP2C9. When amiodarone is added to a stable warfarin regimen, it severely decreases warfarin clearance, leading to elevated serum warfarin concentrations, a dramatically prolonged prothrombin time (PT)/international normalized ratio (INR), and an increased risk of severe bleeding. Standard medical management requires immediately checking the INR upon amiodarone initiation and preemptively reducing the warfarin dose by 25% to 50%, followed by close, frequent laboratory monitoring until a new steady state is achieved.

Step-by-Step Solution

1
Identify the patient's current active medications and conditions.
The patient is taking warfarin for a mechanical aortic valve and recently started amiodarone for atrial fibrillation.
Establishing the medication list is the first step in identifying potential drug-drug interactions.
2
Analyze the pharmacokinetic relationship between the newly added drug and the existing regimen.
Amiodarone is a potent inhibitor of the cytochrome P450 enzyme CYP2C9, which is primarily responsible for the metabolism of warfarin.
Understanding enzyme inhibition is critical to predicting changes in serum drug levels.
3
Determine the necessary clinical intervention based on the anticipated physiologic effect.
Because warfarin clearance will be reduced, serum levels will rise, leading to a supratherapeutic INR. The correct action is to immediately check the INR and empirically reduce the warfarin dose.
Proactive dose reduction prevents severe hemorrhagic complications associated with supratherapeutic anticoagulation.

Key Concept

When amiodarone is initiated in a patient taking warfarin, the amiodarone inhibits CYP2C9-mediated warfarin metabolism. The physician must monitor the prothrombin time/INR closely and empirically reduce the warfarin dose (typically by 25% to 50%) to prevent dangerous bleeding.
Rate this question

Topics

Monitoring and Treatment Evaluation

More questions from this topic